PARG and pancreatic ductal adenocarcinoma: Whilst no previous studies have explored the pharmacological effect of combining PARG and topoisomerase 1 inhibitors in cancer, two studies led by Dr. Jonathan R. Brody have reported a synergistic effect between PARG inhibitors and 5FU or CF10 (a next‐generation fluoropyrimidine) in pancreatic ductal adenocarcinoma.49, 50